PL3842425T3 - Nowy inhibitor będący pochodną chinoliny - Google Patents
Nowy inhibitor będący pochodną chinolinyInfo
- Publication number
- PL3842425T3 PL3842425T3 PL19851019.0T PL19851019T PL3842425T3 PL 3842425 T3 PL3842425 T3 PL 3842425T3 PL 19851019 T PL19851019 T PL 19851019T PL 3842425 T3 PL3842425 T3 PL 3842425T3
- Authority
- PL
- Poland
- Prior art keywords
- quinoline derivative
- novel quinoline
- derivative inhibitor
- inhibitor
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810971406 | 2018-08-24 | ||
| CN201811403888 | 2018-11-23 | ||
| CN201910126817 | 2019-02-20 | ||
| CN201910490783 | 2019-06-06 | ||
| PCT/CN2019/102230 WO2020038460A1 (zh) | 2018-08-24 | 2019-08-23 | 一种新型的喹啉衍生物抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3842425T3 true PL3842425T3 (pl) | 2024-08-19 |
Family
ID=69591988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19851019.0T PL3842425T3 (pl) | 2018-08-24 | 2019-08-23 | Nowy inhibitor będący pochodną chinoliny |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220073496A1 (pl) |
| EP (1) | EP3842425B1 (pl) |
| JP (2) | JP2021536436A (pl) |
| KR (1) | KR102845791B1 (pl) |
| CN (1) | CN110857293B (pl) |
| AU (1) | AU2019323455B9 (pl) |
| BR (1) | BR112021003447A2 (pl) |
| CA (1) | CA3109891A1 (pl) |
| ES (1) | ES2985569T3 (pl) |
| PL (1) | PL3842425T3 (pl) |
| PT (1) | PT3842425T (pl) |
| SG (1) | SG11202101622VA (pl) |
| TW (1) | TWI726397B (pl) |
| WO (1) | WO2020038460A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4036086A1 (en) * | 2019-09-24 | 2022-08-03 | Transthera Sciences (Nanjing), Inc. | Heterocyclic derivative and use thereof |
| TW202126651A (zh) | 2019-09-26 | 2021-07-16 | 美商艾克塞里克斯公司 | 吡啶酮化合物及使用方法 |
| BR112022019517A2 (pt) * | 2020-03-30 | 2022-12-06 | Hutchison Medipharma Ltd | Compostos de amida e usos dos mesmos |
| JP7313536B2 (ja) | 2020-05-07 | 2023-07-24 | エルジー エナジー ソリューション リミテッド | 水分との反応性が緩和された高ニッケル電極シートおよびその製造方法 |
| IT202100022682A1 (it) * | 2021-09-01 | 2023-03-01 | Luigi Frati | Derivati pirimidinici e loro uso nel trattamento di tumori |
| EP4582418A1 (en) | 2022-08-30 | 2025-07-09 | TransThera Sciences (Nanjing), Inc. | Crystalline form of quinoline derivative inhibitor, preparation method therefor and use thereof |
| CN115894198B (zh) * | 2022-11-04 | 2024-05-17 | 浙江永太科技股份有限公司 | Qulipta的关键中间体1-(2,3,6-三氟苯基)丙烷-2-酮的制备方法 |
| CN117534655B (zh) * | 2023-11-13 | 2024-08-30 | 复旦大学 | 一种喹诺酮类化合物及其制备方法和用途 |
| CN119074713B (zh) * | 2024-08-07 | 2025-10-31 | 中国医学科学院药用植物研究所 | L-nrb在制备治疗肌萎缩侧索硬化症的药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| CA2712959C (en) * | 2008-01-22 | 2015-06-23 | Vernalis (R & D) Ltd | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| TWI365185B (en) * | 2008-07-24 | 2012-06-01 | Lilly Co Eli | Amidophenoxyindazoles useful as inhibitors of c-met |
| US8569295B2 (en) * | 2009-08-06 | 2013-10-29 | Merck Patent Gmbh | Bicyclic urea compounds |
| WO2011139891A1 (en) * | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
| WO2013022766A1 (en) * | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| JP6051434B2 (ja) * | 2011-11-14 | 2016-12-27 | イグニタ、インク． | ＡＸＬおよびｃ−ＭＥＴキナーゼ阻害剤としてのウラシル誘導体 |
| SG11201404505PA (en) * | 2012-01-31 | 2014-10-30 | Daiichi Sankyo Co Ltd | Pyridone derivative |
| EP3184121A3 (en) * | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
| WO2014145015A2 (en) * | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
| HUE037579T2 (hu) * | 2013-12-26 | 2018-09-28 | Ignyta Inc | Pirazolo[1,5-a]piridin-származékok és módszerek alkalmazásukra |
| EP3239147B9 (en) * | 2014-12-25 | 2020-01-08 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
| HUE049856T2 (hu) * | 2015-04-14 | 2020-10-28 | Qurient Co Ltd | Kinolin-származékok mint TAM RTK inhibitorok |
| CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
| JP6934261B2 (ja) * | 2017-05-24 | 2021-09-15 | アビスコ セラピューティクス カンパニー リミテッド | Ｎ−（アザアリール）シクロラクタム−１−カルボキサミド誘導体、その製造方法および応用 |
| CN110520416B (zh) * | 2017-10-26 | 2022-06-03 | 北京越之康泰生物医药科技有限公司 | 多取代吡啶酮类衍生物、其制备方法及其医药用途 |
| CN111372925B (zh) * | 2017-11-24 | 2022-09-02 | 南京明德新药研发有限公司 | 作为c-MET/AXL抑制剂的尿嘧啶类化合物 |
| UY38349A (es) * | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| UY38536A (es) * | 2019-01-03 | 2020-08-31 | Array Biopharma Inc | Compuestos de quinolina como inhibidores de quinasas tam y met |
-
2019
- 2019-08-23 PL PL19851019.0T patent/PL3842425T3/pl unknown
- 2019-08-23 WO PCT/CN2019/102230 patent/WO2020038460A1/zh not_active Ceased
- 2019-08-23 CA CA3109891A patent/CA3109891A1/en active Pending
- 2019-08-23 CN CN201910785074.3A patent/CN110857293B/zh active Active
- 2019-08-23 JP JP2021510026A patent/JP2021536436A/ja active Pending
- 2019-08-23 EP EP19851019.0A patent/EP3842425B1/en active Active
- 2019-08-23 KR KR1020217008562A patent/KR102845791B1/ko active Active
- 2019-08-23 ES ES19851019T patent/ES2985569T3/es active Active
- 2019-08-23 SG SG11202101622VA patent/SG11202101622VA/en unknown
- 2019-08-23 PT PT198510190T patent/PT3842425T/pt unknown
- 2019-08-23 BR BR112021003447-1A patent/BR112021003447A2/pt unknown
- 2019-08-23 US US17/268,309 patent/US20220073496A1/en active Pending
- 2019-08-23 AU AU2019323455A patent/AU2019323455B9/en active Active
- 2019-08-26 TW TW108130427A patent/TWI726397B/zh active
-
2024
- 2024-01-26 JP JP2024010530A patent/JP2024056742A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110857293A (zh) | 2020-03-03 |
| CA3109891A1 (en) | 2020-02-27 |
| EP3842425A4 (en) | 2022-05-18 |
| AU2019323455B9 (en) | 2024-10-24 |
| EP3842425B1 (en) | 2024-05-22 |
| WO2020038460A1 (zh) | 2020-02-27 |
| KR102845791B1 (ko) | 2025-08-13 |
| PT3842425T (pt) | 2024-07-02 |
| AU2019323455B2 (en) | 2024-07-11 |
| TWI726397B (zh) | 2021-05-01 |
| SG11202101622VA (en) | 2021-03-30 |
| BR112021003447A2 (pt) | 2021-05-18 |
| KR20210049862A (ko) | 2021-05-06 |
| JP2024056742A (ja) | 2024-04-23 |
| JP2021536436A (ja) | 2021-12-27 |
| AU2019323455A1 (en) | 2021-04-01 |
| TW202021589A (zh) | 2020-06-16 |
| EP3842425A1 (en) | 2021-06-30 |
| CN110857293B (zh) | 2023-01-10 |
| ES2985569T3 (es) | 2024-11-06 |
| US20220073496A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106520VA (en) | Kif18a inhibitors | |
| ZA201905811B (en) | Novel inhibitors | |
| SG11202101622VA (en) | Novel quinoline derivative inhibitor | |
| IL275207A (en) | An oxyfluoropiperidine derivative as a kinase inhibitor | |
| SG11202004918XA (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| SG11202010024UA (en) | New quinoline derivatives | |
| GB201705971D0 (en) | Inhibitor compounds | |
| EP3447058A4 (en) | NEW WIDE SPECTRUM LACTAMASE INHIBITOR | |
| IL281634A (en) | Diacosocyclobutanylamino-3-hydroxy-picoline modified amide and its use as a CCR6 inhibitor | |
| IL274036A (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione compounds as P2X3 inhibitors | |
| IL290964A (en) | A 2-aminoquinazolinone derivative | |
| GB201819126D0 (en) | Inhibitor compounds | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| SG11202005870RA (en) | Novel mtor inhibitor compounds | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| SG11202007979UA (en) | Dihydrochromene derivative | |
| SG11202006837XA (en) | Dihydroindolizinone derivative | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201708999D0 (en) | Recrystallization Inhibitor | |
| HK40102998A (zh) | 新的抑制剂 | |
| TWI906880B (zh) | 喹啉衍生物 | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| HK40058334A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |